Equity Overview
Price & Market Data
Price: $1.21
Daily Change: -$0.0299 / 2.47%
Range: $1.06 - $1.22
Market Cap: $4,032,856
Volume: 830,792
Performance Metrics
1 Week: -9.05%
1 Month: -14.21%
3 Months: -74.75%
6 Months: -91.42%
1 Year: -93.27%
YTD: -86.33%
Company Details
Employees: 6
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases. It develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-101, an IL13Ra2 CAR T cell program for glioblastoma; and MB-108 for the treatment of herpes simplex virus-1 oncolytic virus C134. The company was incorporated in 2015 and is headquartered in Waltham, Massachusetts.